Cargando…

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Cognetti, Francesco, Masetti, Riccardo, Fabi, Alessandra, Bianchi, Giulia, Santini, Donatella, Rognone, Alessia, Catania, Giovanna, Angelucci, Domenico, Naso, Giuseppe, Giuliano, Mario, Vassalli, Lucia, Vici, Patrizia, Scognamiglio, Giovanni, Generali, Daniele, Zambelli, Alberto, Colleoni, Marco, Tinterri, Corrado, Scanzi, Francesco, Vigna, Leonardo, Scavina, Paola, Gamucci, Teresa, Marrazzo, Emilia, Scinto, Angelo Fedele, Berardi, Rossana, Fabbri, Maria Agnese, Pinotti, Graziella, Franco, Daniela, Terribile, Daniela Andreina, Tonini, Giuseppe, Cianniello, Daniela, Barni, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099872/
https://www.ncbi.nlm.nih.gov/pubmed/33953182
http://dx.doi.org/10.1038/s41523-021-00246-4
_version_ 1783688665169395712
author Cognetti, Francesco
Masetti, Riccardo
Fabi, Alessandra
Bianchi, Giulia
Santini, Donatella
Rognone, Alessia
Catania, Giovanna
Angelucci, Domenico
Naso, Giuseppe
Giuliano, Mario
Vassalli, Lucia
Vici, Patrizia
Scognamiglio, Giovanni
Generali, Daniele
Zambelli, Alberto
Colleoni, Marco
Tinterri, Corrado
Scanzi, Francesco
Vigna, Leonardo
Scavina, Paola
Gamucci, Teresa
Marrazzo, Emilia
Scinto, Angelo Fedele
Berardi, Rossana
Fabbri, Maria Agnese
Pinotti, Graziella
Franco, Daniela
Terribile, Daniela Andreina
Tonini, Giuseppe
Cianniello, Daniela
Barni, Sandro
author_facet Cognetti, Francesco
Masetti, Riccardo
Fabi, Alessandra
Bianchi, Giulia
Santini, Donatella
Rognone, Alessia
Catania, Giovanna
Angelucci, Domenico
Naso, Giuseppe
Giuliano, Mario
Vassalli, Lucia
Vici, Patrizia
Scognamiglio, Giovanni
Generali, Daniele
Zambelli, Alberto
Colleoni, Marco
Tinterri, Corrado
Scanzi, Francesco
Vigna, Leonardo
Scavina, Paola
Gamucci, Teresa
Marrazzo, Emilia
Scinto, Angelo Fedele
Berardi, Rossana
Fabbri, Maria Agnese
Pinotti, Graziella
Franco, Daniela
Terribile, Daniela Andreina
Tonini, Giuseppe
Cianniello, Daniela
Barni, Sandro
author_sort Cognetti, Francesco
collection PubMed
description Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score(®) (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS(®) results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use.
format Online
Article
Text
id pubmed-8099872
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80998722021-05-10 PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy Cognetti, Francesco Masetti, Riccardo Fabi, Alessandra Bianchi, Giulia Santini, Donatella Rognone, Alessia Catania, Giovanna Angelucci, Domenico Naso, Giuseppe Giuliano, Mario Vassalli, Lucia Vici, Patrizia Scognamiglio, Giovanni Generali, Daniele Zambelli, Alberto Colleoni, Marco Tinterri, Corrado Scanzi, Francesco Vigna, Leonardo Scavina, Paola Gamucci, Teresa Marrazzo, Emilia Scinto, Angelo Fedele Berardi, Rossana Fabbri, Maria Agnese Pinotti, Graziella Franco, Daniela Terribile, Daniela Andreina Tonini, Giuseppe Cianniello, Daniela Barni, Sandro NPJ Breast Cancer Article Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score(®) (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS(®) results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use. Nature Publishing Group UK 2021-05-05 /pmc/articles/PMC8099872/ /pubmed/33953182 http://dx.doi.org/10.1038/s41523-021-00246-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Cognetti, Francesco
Masetti, Riccardo
Fabi, Alessandra
Bianchi, Giulia
Santini, Donatella
Rognone, Alessia
Catania, Giovanna
Angelucci, Domenico
Naso, Giuseppe
Giuliano, Mario
Vassalli, Lucia
Vici, Patrizia
Scognamiglio, Giovanni
Generali, Daniele
Zambelli, Alberto
Colleoni, Marco
Tinterri, Corrado
Scanzi, Francesco
Vigna, Leonardo
Scavina, Paola
Gamucci, Teresa
Marrazzo, Emilia
Scinto, Angelo Fedele
Berardi, Rossana
Fabbri, Maria Agnese
Pinotti, Graziella
Franco, Daniela
Terribile, Daniela Andreina
Tonini, Giuseppe
Cianniello, Daniela
Barni, Sandro
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_full PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_fullStr PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_full_unstemmed PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_short PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_sort pondx: real-life utilization and decision impact of the 21-gene assay on clinical practice in italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099872/
https://www.ncbi.nlm.nih.gov/pubmed/33953182
http://dx.doi.org/10.1038/s41523-021-00246-4
work_keys_str_mv AT cognettifrancesco pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT masettiriccardo pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT fabialessandra pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT bianchigiulia pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT santinidonatella pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT rognonealessia pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT cataniagiovanna pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT angeluccidomenico pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT nasogiuseppe pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT giulianomario pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT vassallilucia pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT vicipatrizia pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT scognamigliogiovanni pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT generalidaniele pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT zambellialberto pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT colleonimarco pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT tinterricorrado pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT scanzifrancesco pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT vignaleonardo pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT scavinapaola pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT gamucciteresa pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT marrazzoemilia pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT scintoangelofedele pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT berardirossana pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT fabbrimariaagnese pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT pinottigraziella pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT francodaniela pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT terribiledanielaandreina pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT toninigiuseppe pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT cianniellodaniela pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
AT barnisandro pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly